Dialysis patients treated with a low protein diet with keto analogues had lower levels of parathyroid hormone than those on a normal diet, meta-analysis shows.
By the third month of treatment, 59% of etelcalcetide recipients had reached target iPTH levels of 60 to 240 pg/mL compared with just 1.3% of placebo recipients.
Parathyroidectomy for hyperparathyroidism in CKD patients is associated with a 30-day readmission rate of 17.2%.
By 52 weeks, 87.5% of patients had reached an intact parathyroid hormone target range of 60 to 240 pg/mL.
Calcifediol is possibly more effective at alleviating 25(OH)D deficiency and reducing parathyroid hormone compared with other nutritional vitamin D therapies.
Surgical complications and symptom improvement, for example, did not differ significantly between total parathyroidectomy with and without autotransplantation.
The risk for premature death increased by 62% and 42% for stage 3 CKD patients with vitamin D deficiency and elevated parathyroid hormone levels, respectively.
Single-center study reveals a hospitalization rate of 14% following total parathyroidectomy without autotransplantation.
Meta-analysis shows comparable efficacy in lowering iPTH, but analyses of patient-centered outcomes such as mortality and cardiovascular death were not possible.
Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.
New survey shows that out-of-pocket costs are a major concern.
Bone mineral density in the lumbar spine and femoral neck increased over time in hemodialysis patients who underwent total parathyroidectomy without autotransplantation.
SHPT in those aged 65 years or older is associated with lower eGFR, low levels of 25-hydroxyvitamin D, and use of furosemide.
After parathyroidectomy, morbidity and mortality rates were considerably higher in patients with secondary and tertiary vs primary hyperparathyroidism.
Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.
The risk of death more than tripled with iPTH levels above 600 pg/mL at 1 week after surgery.
Meta-analysis reveals a lower risk of recurrence and persistence of SHPT when total parathyoidectomy is performed without transplanting parathyroid tissue.
Among other changes, the new KDIGO guidelines highlight the potential dangers of hypercalcemia.
From 2003 to 2011 there was a 26.7% decrease in in-hospital mortality rate after hip fracture.
Patients often received sodium thiosulfate with other therapies.
Typically, about 2% to 20% of SHPT patients experience recurrence or persistence after conventional parathyroidectomy procedures, likely due to residual parathyroid tissue.
In a study of CKD patients, intact PTH levels remained stable those receiving cholecalciferol 8000 IU daily but increased in placebo recipients.
Higher CTR was associated with greater risks of death from cardiovascular disease and other causes.
Researchers found lower all-cause mortality for cinacalcet-treated patients concomitantly treated with vitamin D and phosphate binders, for example.
Up to half of transplant patients might experience tertiary hyperparathyroidism.
In a study of hemodialysis patients, mortality risk increased along with phosphorus level, particularly among patients with higher residual renal urea clearance.
The researchers found that patients of high-volume surgeons had a lower rate of vocal cord paralysis compared to patients of low-volume surgeons.
At 18 months, PTH levels were within target for 67% and 68% of participants who initiated etelcalcetide at 2.5 mg and 5 mg, respectively.
Nearly twice as many patients achieved the target phosphorus range after a year of taking the phosphate binder, regardless of iPTH level.
Cinacalcet treatment may serve as a bridge to parathyroidectomy or as an alternative, researchers say.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)